Hydroxyurea therapy (HT) prevents primary stroke and controls iron overload in children with sickle-cell anaemia (SCA). It is an effective alternative to lifelong transfusions -- the current standard of care -- that cause iron overload, say researchers.
Daratumumab (DARA) in combination with lenalidomide and dexamethasone (LEN/DEX) can be safely administered to patients with relapsed or relapsed and refractory multiple myeloma (MM), according to a phase I/II study presented at the recent Annual Meeting of the American Society of Hematology (ASH).
Beta-thalassemia patients who need lifelong monthly blood transfusions because of a genetic mutation that causes them to underproduce haemoglobin may benefit from an experimental gene therapy that reduced or completely eliminated the need for transfusions in 13 patients with the disorder, new data from the ongoing Northstar study showed.
Idelalisib added to a standard care regimen of bendamustine and rituximab (BR) reduced the risk of disease progression and death compared to BR alone in relapsed or refractory chronic lymphocytic leukaemia (CLL) patients, in a phase III trial. [ASH 2015, abstract LBA-5]
Genetically engineered T cells that target and destroy plasma cells may have the potential to cure patients with advanced multiple myeloma (MM), according to the results of a small, phase I/II trial in which one patient with over 90 percent of bone marrow cells affected was cleared of myeloma 1 month after treatment and researchers say he remains in stringent complete remission. [ASH 2015, abstract LBA 1]
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Pharmacy - Malaysia digital copy today!
Pearl Toh spoke with Dr Teh Ming Ming, senior consultant at the Department of Endocrinology, Singapore General Hospital (SGH), on the major challenges of diagnosing and managing diabetes in primary care, in conjunction with the World Diabetes Day on 14 November. Awareness of the symptoms of diabetes is important, and patients should be empowered to manage their conditions.
New drug applications approved by US FDA as of 1 - 15 June 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.